Long-term effects of aromatase inhibitors on bone

Journal of Steroid Biochemistry and Molecular Biology

Volumn 95, Issue 1-5, 2005, Pages 151-154

  Eastell, Richard ^a   Hannon, Rosemary ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Aromatase; Fractures; Oestradiol

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EXEMESTANE; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; TAMOXIFEN;

BONE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; ESTROGEN BLOOD LEVEL; FRACTURE; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; RISK ASSESSMENT; VERTEBRA FRACTURE;

AROMATASE INHIBITORS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; BREAST NEOPLASMS; ESTROGENS; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; SPINAL FRACTURES;

EID: 23744511536     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.04.009     Document Type: Conference Paper

References (35)

1. The ATAC Trialists Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (June (9324)) (2002) 2131-2139.
2. M. Baum, A. Buzdar, J. Cuzick, J. Forbes, J. Houghton, A. Howell, and T. Sahmoud Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses Cancer 98 November (9) 2003 1802 1810
3. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S.E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, A.S. Coates, E. Bajetta, D. Dodwell, R.E. Coleman, L.J. Fallowfield, E. Mickiewicz, J. Andersen, P.E. Lonning, G. Cocconi, A. Stewart, N. Stuart, C.F. Snowdon, M. Carpentieri, G. Massimini, and J.M. Bliss A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N. Engl. J. Med. 350 March (11) 2004 1081 1092
4. P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, M.J. Piccart, M. Castiglione, D. Tu, L.E. Shepherd, K.I. Pritchard, R.B. Livingston, N.E. Davidson, L. Norton, E.A. Perez, J.S. Abrams, P. Therasse, M.J. Palmer, and J.L. Pater A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N. Engl. J. Med. 349 November (19) 2003 1793 1802
5. P.D. Delmas, K.E. Ensrud, J.D. Adachi, K.D. Harper, S. Sarkar, C. Gennari, J.Y. Reginster, H.A. Pols, R.R. Recker, S.T. Harris, W. Wu, H.K. Genant, D.M. Black, and R. Eastell Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial J. Clin. Endocrinol. Metab. 87 August (8) 2002 3609 3617
6. D.M Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, M.C. Nevitt, D.C. Bauer, H.K. Genant, W.L. Haskell, R. Marcus, S.M. Ott, J.C. Torner, S.A. Quandt, T.F. Reiss, and K.E. Ensrud Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 9041 1996 1535 1541
7. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90 September (18) 1998 1371 1388
8. J. Cuzick, J. Forbes, R. Edwards, M. Baum, S. Cawthorn, A. Coates, A. Hamed, A. Howell, and T. Powles First results from the international breast cancer intervention study (IBIS-I): a randomised prevention trial Lancet 360 September (9336) 2002 817 824
9. A.B. Grey, J.P. Stapleton, M.C. Evans, M.A. Tatnell, R.W. Ames, and I.R. Reid The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women Am. J. Med. 99 6 1995 636 641
10. A. Resch, E. Biber, M. Seifert, and H. Resch Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer Acta Oncol. 37 7-8 1998 661 664
11. M.B. Marttunen, P. Hietanen, A. Tiitinen, and O. Ylikorkala Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients J. Clin. Endocrinol. Metab. 83 April (4) 1998 1158 1162
12. B. Kristensen, B. Ejlertsen, P. Dalgaard, L. Larsen, S.N. Holmegaard, I. Transbol, and H.T. Mouridsen Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study J. Clin. Oncol. 12 May (5) 1994 992 997
13. R.L. Ward, G. Morgan, D. Dalley, and P.J. Kelly Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women Bone Miner. 22 1993 87 94
14. T.J. Powles, T. Hickish, J.A. Kanis, A. Tidy, and S. Ashley Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women J. Clin. Oncol. 14 January (1) 1996 78 84
15. R.R. Love, R.B. Mazess, H.S. Barden, S. Epstein, P.A. Newcomb, V.C. Jordan, P.P. Carbone, and D.L. Demets Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N. Engl. J. Med. 326 1992 852 856
16. S. Barni, P. Lissoni, G. Tancini, A. Ardizzoia, and M. Cazzaniga Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women Tumori 82 January (1) 1996 65 67
17. J.A. Kalef-Ezra, N. Pavlidis, G. Klouvas, A. Karantanas, I. Hatzikonstantinou, and D. Glaros Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen Breast Cancer Res. Treat. 37 2 1996 161 168
18. M.B. Marttunen, P. Hietanen, A. Titinen, H.J. Roth, L. Viinikka, and O. Ylikorkala Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer Calcif. Tissue Int. 65 November (5) 1999 365 368
19. R. Eastell, R.A. Hannon, J. Cuzick, G. Clack, and J.E. Adams Effect of anastrozole on bone density and bone turnover: results of the arimadex, tamoxifen, alone or in combination (ATAC) study J. Bone Miner. Res. 17 Suppl. 1 2002 S165
20. R. Eastell, R.A. Hannon, J. Cuzick, G. Clack, and J.E. Adams Effect of anastrozole on bone mineral density: 2-year results of the ATAC trial J. Bone Miner. Res. 18 Suppl. 1 2003 S312
21. E. Bajetta, N. Zilembo, and E. Bichisao Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact J. Clin. Oncol. 20 July (13) 2002 3039 3040
22. C. Harper-Wynne, G. Ross, N. Sacks, J. Salter, N. Nasiri, J. Iqbal, R. A'Hern, and M. Dowsett Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention Cancer Epidemiol. Biomarkers Prev. 11 July (7) 2002 614 621
23. H.M. Heshmati, S. Khosla, S.P. Robins, W.M. O'Fallon, L.J. Melton III, and B.L. Riggs Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women J. Bone Miner. Res. 17 January (1) 2002 172 178
24. A. Martinetti, N. Zilembo, L. Ferrari, G. Massimini, A. Polli, T. La I, R. Giovanazzi, P. Pozzi, P. Bidoli, C.D. De, E. Seregni, E. Bombardieri, and E. Bajetta Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs. megestrol acetate Anticancer Res. 23 July (4) 2003 3485 3491
25. S. Khosla, L.J. Melton III, E.J. Atkinson, and W.M. O'Fallon Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men J. Clin. Endocrinol. Metab. 86 August (8) 2001 3555 3561
26. P. Garnero, E. Sornay-Rendu, B. Claustrat, and P.D. Delmas Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J. Bone Miner. Res. 15 8 2000 1526 1536
27. R.D. Chapurlat, D.C. Bauer, and S.R. Cummings Association between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: study of osteoporotic fractures Bone 29 October (4) 2001 381 387
28. A. Rogers, G. Saleh, R.A. Hannon, D. Greenfield, and R. Eastell Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women J. Clin. Endocrinol. Metab. 87 October (10) 2002 4470 4475
29. B Ettinger, A. Pressman, P. Sklarin, D.C. Bauer, J.A. Cauley, and S.R. Cummings Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures J. Clin. Endocrinol. Metab. 83 7 1998 2239 2243
30. S.R. Cummings, W.S. Browner, D. Bauer, K. Stone, K. Ensrud, S. Jamal, and B. Ettinger Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group N. Engl. J. Med. 339 September (11) 1998 733 738
31. R.D. Chapurlat, P. Garnero, G. Breart, P.J. Meunier, and P.D. Delmas Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study J. Bone Miner. Res. 15 September (9) 2000 1835 1841
32. B.E. Hillner, J.N. Ingle, R.T. Chlebowski, J. Gralow, G.C. Yee, N.A. Janjan, J.A. Cauley, B.A. Blumenstein, K.S. Albain, A. Lipton, and S. Brown American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J. Clin. Oncol. 21 November (21) 2003 4042 4057
33. J.A. Kanis, O. Johnell, A. Oden, A. Dawson, C. De Laet, and B. Jonsson Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds Osteoporos. Int. 12 December (12) 2001 989 995
34. N.H. Bell, B.W. Hollis, J.R. Shary, D.R. Eyre, R. Eastell, A. Colwell, and R.G.G. Russell Diclofenac sodium inhibits bone resorption in postmenopausal women Am. J. Med. 96 4 1994 349 353
35. T.P. van Staa, H.G. Leufkens, and C. Cooper Use of nonsteroidal anti-inflammatory drugs and risk of fractures Bone 27 October (4) 2000 563 568